RE: RE: RE: RE: RE: TAErudite & mediascan(m)59.....
I am certainly not a doctor nor am I an investment specialist or advisor. I am simply an avergae investor like most of us; except those who are paid to pump/bash stocks in these forums....???.
What I do now from my experience over the past few years is that there are many pharma companies out there with many products. The vast majority of these products fail and never make it to market. I have seen far more effective/positive results on differing drugs that have not been granted Phase III. I've also seen drugs that have had worse results that have been advanced to Phase III for one reason or another. I agree that yes this is possible.
However, more money is required to even fund that trial or any others for that matter, and that is what really matters for the share price to move right now. You can't drive it higher without positive results. Further, the low numbers of people enrolled in the Phase II study does not auger well for advanced trials. I quote directly from the FDA's website:
Phase 1 includes the initial introduction of an investigational new drug into humans. These studies are usually conducted in healthy volunteer subjects. These studies are designed to determine the metabolic and pharmacological actions of the drug in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness. Phase 1 studies also evaluate drug metabolism, structure-activity relationships, and the mechanism of action in humans. The total number of subjects included in Phase 1 studies is generally in the range of twenty to eighty.
Phase 2 includes the early controlled clinical studies conducted to obtain some preliminary data on the effectiveness of the drug for a particular indication or indications in patients with the disease or condition. This phase of testing also helps determine the common short-term side effects and risks associated with the drug. Phase 2 studies usually involve several hundred people.
Phase 3 studies are intended to gather the additional information about effectiveness and safety that is needed to evaluate the overall benefit-risk relationship of the drug. Phase 3 studies also provide an adequate basis for extrapolating the results to the general population and transmitting that information in the physician labeling. Phase 3 studies usually include several hundred to several thousand people.
As you can see, the number of people involved in their Phase II was closer to the numbers required of a Phase I trial. As you can also see, it is possible that the drug could advance to Phase III given the objectives of each stage (Phase II focus on effectiveness vs. Phase III focus on risk-benefit). However, unless the drug suddenly has a miraculous improvement in effectiveness, it is unlikely to do well in Phase III, if it even gets that far.
All I am trying to get accross is that this is not a pure growth play that is a sure thing. There is likely to be some price appreciation in the near-term, but there is also a great possibility of dillution. In my opinion, the likelihood of dillution is far greater than an appreciation in the near-term to $.30 or even $2.00+ as has been indicated by others.
*Full disclosure (since my credibility is lost).....20,000 @
.057 avg cost with fees.*